Longer-term results updating a study of teprotumumab show improvements up to 72 weeks. Medscape Medical News
Patients with type 2 diabetes given statin or fibrate lipid-lowering therapy have both a reduced risk of developing diabetic retinopathy and being treated for the condition, Japanese claims data show. Medscape Medical News
Contrary to previous reports, glucagon-like receptor-1 agonists (GLP-1 RAs) do not appear to increase patients’ risk of diabetic retinopathy, according to findings from the U.K. Clinical Practice Research Datalink (CPRD). Reuters Health Information
‘Such a remarkable decrease in microvascular complications has rarely been demonstrated by any form of diabetes therapy,’ write the authors of an editorial accompanying the study. Medscape Medical News
The ACP reviewed relevant studies but came to conclusions ‘not germane to the way we treat patients with type 2 diabetes today,’ says Dr Anne Peters.
Medscape Diabetes & Endocrinology
Adding mycophenolate mofetil to standard therapy for severe Graves’ orbitopathy shows some benefits in a post hoc analysis, but added radiotherapy has no effect and azathioprine benefits appear inconclusive. Medscape Medical News
Diabetes patients face a twofold increased risk of developing cataracts compared with other patients. The risk rises to more than fivefold among those aged 45 to 54 years, new UK registry data suggest. Medscape Medical News
Pretreatment with agents blocking vascular endothelial growth factor (anti-VEGF) offers several advantages in patients with complicated proliferative diabetic retinopathy (PDR) undergoing vitrectomy, according to pooled data. Reuters Health Information
Patients who were diagnosed with type 2 diabetes at age 18 to 45 (early-onset) had the highest prevalence of cardiovascular risk factors and worst glycemic control in a Danish national cohort. Medscape Medical News
The nod from the European Medicines Agency’s advisory panel follows approval by the US Food and Drug Administration. International Approvals
A “deep learning system” can be taught to determine whether or not diabetic retinopathy is present across different ethnicities in a variety of settings.
Medscape Medical News
Improvements seen in overall responses, various clinical measures compared with methylprednisolone alone. Medscape Medical News
Contrary to hypothesis, neurodysfunction preceded microvascular impairment in only a minority of diabetic-retinopathy patients, but in that subgroup, neuroprotective eyedrops arrested disease progression. Medscape Medical News
Roux-en-Y gastric bypass reduced diabetic retinopathy risk regardless of postsurgery diabetes status in a two-phase trial; a second study confirms obesity-related microvascular changes are reversible. Medscape Medical News
UPDATED // The large Japanese DOIT3 trial tells clinicians that optimal lipid, blood pressure, and, glycemic control are important to reduce microvascular and macrovascular complications in type 2 diabetes. Medscape Medical News
It might make sense to screen everyone with diabetes for retinopathy using optical coherence tomography (OCT), new research suggests. Medscape Medical News
Patients who developed retinopathy complications with semaglutide were more likely to have had preexisting retinopathy, poorer baseline glycemic control, and more robust glucose lowering in the trial. Medscape Medical News
Treating diabetic macular edema with anti-vascular endothelial growth factor (anti-VEGF) may lead to improvements in diabetic retinopathy severity for up to two years, particularly in patients with nonproliferative disease, researchers say. Reuters H…
Originally developed as a cancer drug, teprotumumab shows “unheralded” efficacy at relieving symptoms of thyroid eye disease, one investigator said.
Medscape Medical News
Long-term data from the Diabetes Control and Complications Trial and its follow-up suggest retina exam frequency can be individualized based on initial degree of retinopathy and HbA1c. Medscape Medical News